📚 Part of the Cardiovascular Landmark Trials guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #32
Category: Lipids & Statins · Diabetes & Cardiovascular Prevention | Design: Multicentre, double-blind, placebo-controlled RCT | n: 2,838 | Follow-up: 3.9 years (median; stopped early)
📋 Summary
Authors: Colhoun HM et al., for the CARDS Investigators
Journal: Lancet 2004;364:685–696 | DOI: 10.1016/S0140-6736(04)16895-5
The Collaborative Atorvastatin Diabetes Study enrolled 2,838 patients aged 40–75 years with type 2 diabetes mellitus, no documented previous cardiovascular disease, an LDL-cholesterol of 4.14 mmol/L or below, and at least one of the following cardiovascular risk factors: retinopathy, albuminuria, current smoking, or hypertension, from 132 centres in the United Kingdom and Ireland. Participants were randomised to atorvastatin 10 mg daily or placebo. The trial was terminated approximately two years early because the pre-specified early stopping rule for efficacy had been met. At the time of stopping (median follow-up 3.9 years), 127 placebo patients (2.46 per 100 person-years) and 83 atorvastatin patients (1.54 per 100 person-years) had experienced a primary cardiovascular event — acute coronary event, coronary revascularisation, or stroke — a 37% relative rate reduction (95% CI 17 to 52%; p=0.001). Acute coronary events were reduced by 36%, coronary revascularisations by 31%, and stroke by 48% (95% CI 11 to 69%). All-cause mortality was reduced by 27% (−48 to 1; p=0.059), a result of borderline significance given the early stopping. Atorvastatin was well tolerated with no excess adverse events. The expected treatment effect extrapolated to the originally planned 4-year follow-up would prevent at least 37 major vascular events per 1,000 patients treated for 4 years.
📊 Key Findings
| Outcome | Atorvastatin 10 mg | Placebo | Effect Size |
|---|---|---|---|
| Primary composite (ACS, revascularisation, stroke) | 1.54/100 PY | 2.46/100 PY | 37% rate reduction (17–52%) · p=0.001 |
| Acute coronary events | — | — | 36% reduction · p=0.007 |
| Stroke | — | — | 48% reduction (11–69%) · p=0.016 |
| Coronary revascularisation | — | — | 31% reduction · NS individually |
| All-cause mortality | — | — | 27% reduction (−48 to 1) · p=0.059 |
| Projected NNT (4 years) | Approximately 27 to prevent one major vascular event | ||
CARDS
RCT · type 2 diabetes · 3.9 years
Atorvastatin 10 mg cut major cardiovascular events by 37% and stroke by 48% in type 2 diabetes without high LDL. Cardiovascular risk, not LDL level, should drive statin initiation.
💬 Expert Commentary
CARDS was the dedicated primary prevention statin trial for type 2 diabetes, and its early termination due to a strong efficacy signal within four years provided the clearest possible evidence that atorvastatin reduces cardiovascular events in diabetic patients without prior CVD or elevated LDL-cholesterol. The entry criterion of LDL below 4.14 mmol/L was deliberately set to enrol patients who would not have met the entry criteria for earlier secondary prevention statin trials, ensuring that the benefit observed in CARDS represents genuine primary prevention in a population with metabolic risk but not dyslipidaemia as traditionally defined. The 37% event rate reduction in this context, comparable in relative terms to the 4S secondary prevention result, demonstrated that the proportional vascular event benefit of statin therapy in diabetes is independent of baseline LDL level — a finding that directly complemented the HPS conclusion.
The 48% stroke reduction in CARDS is particularly striking and is the largest stroke reduction attributable to statin monotherapy reported in any trial to that date. It is consistent with the growing body of evidence that statins reduce stroke risk through mechanisms beyond LDL lowering, including anti-inflammatory, plaque-stabilising, and endothelial-function effects that may be particularly relevant in the diabetic vasculature. CARDS provided the definitive evidence base for the statement in multiple international diabetes guidelines that all patients with type 2 diabetes above a certain age (variously 40 or 50 years) with any additional cardiovascular risk factor should receive statin therapy regardless of baseline lipid levels, and it remains the primary reference trial for this recommendation. The result also reinforced the broader principle established by HPS: statin therapy in high-risk patients is a cardiovascular risk reduction intervention, not a lipid-normalisation intervention, and the threshold for initiation should be defined by risk rather than by LDL concentration.
Limitations: The trial was stopped early, which may have inflated the effect size estimate. Atorvastatin 10 mg rather than higher-intensity therapy was used; more intensive statin therapy might produce greater benefit. All-cause mortality did not quite reach conventional significance. Entry required at least one additional cardiovascular risk factor beyond diabetes itself, which slightly narrows the absolute applicability. The study was funded by Pfizer.
🔑 BOTTOM LINE
CARDS demonstrated that atorvastatin 10 mg reduces major cardiovascular events by 37% and stroke by 48% in patients with type 2 diabetes and normal to mildly elevated LDL-cholesterol, confirming that statin therapy is indicated in all high-risk diabetic patients regardless of baseline LDL level and establishing the evidence base for universal statin use in primary cardiovascular prevention in type 2 diabetes.
⭐ Clinical Impact Rating: ●●●●● Practice-defining